Published online Apr 26, 2017. doi: 10.13105/wjma.v5.i2.41
Peer-review started: June 16, 2016
First decision: July 27, 2016
Revised: January 14, 2017
Accepted: February 18, 2017
Article in press: February 20, 2017
Published online: April 26, 2017
Core tip: Statins are one of the most commonly prescribed pharmaceutical agents worldwide and atorvastatin remained the largest source of spending in the class. In recent years, emerging experimental evidence suggests that statins may have a potential role in cancer chemoprevention. However, a large number of randomized controlled trials and observational studies published to examine the association between statin use and risk of site specific cancers were given conflicting results. This overview of meta-analyses with variable quality has been shown that the statins may have a potential role in cancer chemoprevention and reduce the risk of colorectal (8%-12%), gastric (27%-44%), hematological (19%), liver (37%-42%), oesophageal (14%-28%), ovarian (21%) and prostate cancer (7%).